RxDoctor Payments DataLook up a doctor →

Hector Cases

Interventional Pain Medicine · Sun City Center, FLNPI 1265491781

Payments from drug & device makers

$635,458in general payments, 2019–2025

Across 564 payments — averaging $1126.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Seikagaku Corporation$602K
  • AbbVie$23K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Medtronic$1K
  • Nalu Medical, Inc.$1K
  • Curonix LLC$1K
  • plus $5K from 42 others

What the payments were for

  • Travel & lodging$1,29411%
  • Food & beverage$10,16588%
  • Education$871%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$635,458 in reported general payments places this provider in the 95th percentile of 278 interventional pain medicine providers in Florida.

See all interventional pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$243,741
Medicare patients
272
Services billed
4,064

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl82$68,654
RelistorMethylnaltrexone Bromide25$67,907
UbrelvyUbrogepant23$42,660
Xtampza ErOxycodone Myristate38$27,402
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen808$24,780
QuliptaAtogepant13$22,545
MovantikNaloxegol Oxalate53$21,148
Buprenorphine83$18,486
NucyntaTapentadol Hcl12$18,029
Oxycodone Hcl923$15,805
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen582$13,249
LinzessLinaclotide11$6,163
Tramadol Hcl395$6,133
OxycontinOxycodone Hcl11$4,357
Pregabalin226$3,936

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta$358$114,085132 claims
AbbVieUbrelvy, Qulipta, Linzess$22,571$71,36847 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$1,931$67,90725 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$41$22,016199 claims
Redhill Biopharma Inc.Movantik$97$21,14853 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 278 interventional pain medicine providers in Florida.

Other interventional pain medicine in Sun City Center

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →